Summary

Overview
Global Natural Killer T-Cell Lymphoma Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Natural Killer T-cell lymphoma is a highly aggressive subtype of non-Hodgkin lymphoma (NHL) strongly associated with Epstein-Barr virus (EBV) infection. The uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called "T cells" and "natural killer (NK) cells.
Treatment for NHL depends on the subtype, stage of the disease, and individual patient factors. The primary treatment modalities include chemotherapy, radiation therapy, immunotherapy, targeted therapy, and stem cell transplantation. The choice of treatment aims to achieve remission, alleviate symptoms, and prolong survival. Treatment may involve a combination of these modalities and is often tailored to each patient's needs.
Furthermore, rising innovations, increasing prevalence of non-hodgkin lymphoma, and an evolving treatment landscape, the integration of modern techniques, such as CRISPR gene-editing, immunotherapy, precision medicine, and AI-enabled clinical trial operations system are the factors that drive the market in the forthcoming years.
Dynamics
Increasing Product Launches
In recent years, new cell types and technologies have been used to overcome challenges posed by current treatments and the nature of the targeted diseases, thus enabling us to treat and cure severe disorders. Lymphomas are a heterogeneous group of malignancies that arise from the clonal proliferation of B cell, T-cell, and natural killer (NK) cell subsets of lymphocytes at different stages of maturation. The products launched for a specific lymphoma are used for treating the subsets.
In January 2023, Loxo Lilly, the oncology unit of Eli Lilly and Company, stated that the U.S. Food and Drug Administration (FDA) approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.
Rising Clinical Trials
The number of registered clinical oncology clinical trials has steadily increased. For instance, according to data from the WHO International Clinical Trials Registry Platform (ICTRP), in 2013, approximately 19,211 trials were registered in this field, and by 2022, that number had grown to 26,396. Recent years have witnessed numerous breakthroughs in oncology clinical trials, spanning immunotherapies, precision medicine, gene therapy, and combination therapy.
Also, Sun Yat-sen University is conducting phase 1 and phase 2 clinical trials to evaluate the safety, tolerability, and efficacy in combination with tislelizumab and mitoxantrone hydrochloride liposome combination treatment in patients with relapsed or refractory Extranodal Natural Killer/T Cell Lymphoma（NKTCL). This trial also investigates the preliminary antitumor efficacy.
Lack of Specific Targeted Therapies
Despite the success of targeted therapies in treating select NHL subtypes, there remains a necessity for more accurate and potent targeted treatments that can address a broader range of NHL subtypes. Limited treatment alternatives for specific NHL subtypes hinder market growth within the field.
For instance, Peripheral T-cell Lymphoma (PTCL) is a heterogeneous group of NHL subtypes with narrow treatment options. Currently, there are no targeted therapies specifically approved for PTCL. Chemotherapy regimens are frequently used, but the prognosis for PTCL patients remains relatively poor. Developing targeted therapies that address the unique characteristics of PTCL subtypes is an unmet need.
Segment Analysis
The global is segmented based on drug class, therapy, route of administration, end user and region.
The Radiotherapy Segment Accounted for Approximately 43.3% of the Market Share
Radiation therapy can ease (palliate) symptoms induced by lymphoma that has spread to internal organs, such as the brain or spinal cord, or when a tumor is causing pain because it’s pressing on nerves. Radiotherapy then targets the leading site of the lymphoma. With curative radiotherapy, this increases the likelihood of destroying the lymphoma. Clinical Trials are performed to evaluate the safety and effectiveness of radiotherapy compared with chemotherapy.
International Extranodal Lymphoma Study Group (IELSG) is conducting a phase 2 clinical trial to evaluate the activity and tolerability of the anti-PD1 agent Pembrolizumab in combination with radiotherapy for the initial treatment of previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible to chemotherapy. All eligible patients will be treated intravenously with standard radiotherapy and concurrent pembrolizumab every three weeks. Intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended for the patients participating in the trial. The estimated completion date is December 2026.
Geographical Analysis
North America accounted for Approximately 41.4% of the Market Share in 2022
Healthcare expenditure in North America is rising due to a growing concern for health among people. The U.S. has the lowest life expectancy at birth, the highest death rates for avoidable or treatable conditions, maternal and infant mortality, and suicide rates.
Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. The American Cancer Society's estimates for non-Hodgkin lymphoma in 2023 are that about 80,550 people (44,880 males and 35,670 females) will be diagnosed with NHL.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global natural killer T-cell lymphoma market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity.
The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting drug development activities worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to pharmaceutical manufacturing industries.
The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of cancer-related research and development activities. This has led to delays in the completion of trials and the availability of new therapies, which has affected the market.
By Drug Class
• Monoclonal Antibodies
• Antibody-Drug Conjugates
• PI3 Kinase Inhibitors
• PD1 Inhibitors
• Immunomodulatory Drugs
• Protease Inhibitors
• BTK/BCL-2 Kinase Inhibitors
• Others
By Therapy
• Radiotherapy
• Immunotherapy
• Targeted Therapy
• Combination Therapy
• Others
By Route of Administration
• Oral
• Parenteral
• Injectables
• Others
By End User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In 2023, Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer’s capabilities and expertise.
Competitive Landscape
The major global players in the natural killer T cell lymphoma market include Beigen, Merck Group, Viracta Therapeutics, PersonGen BioTherapeutics, Thermo Fisher Scientific, AstraZeneca, Gilead Sciences, Astex Pharmaceuticals, Immuneoncia Therapeutics, Corvus Pharmaceuticals among others.
Why Purchase the Report?
• To visualize the global natural killer T cell lymphoma segmentation based on drug class, therapy, route of administration, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of natural killer T cell lymphoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global natural killer T cell lymphoma market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Therapy
3.3. Snippet by Route of Administration
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Product Launches
4.1.1.2. Rising Clinical Trials
4.1.2. Restraints
4.1.2.1. Lack of Specific Targeted Therapies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Monoclonal Antibodies
7.3. Antibody-Drug Conjugates
7.4. PI3 Kinase Inhibitors
7.5. PD1 Inhibitors
7.6. Immunomodulatory Drugs
7.7. Protease Inhibitors
7.8. BTK/BCL-2 Kinase Inhibitors
7.9. Others
8. By Therapy
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.1.2. Market Attractiveness Index, By Therapy
8.2. Radiotherapy
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Immunotherapy
8.4. Targeted Therapy
8.5. Combination Therapy
8.6. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Injectables
9.5. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Ambulatory Surgical Centers
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Russia
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Beigen
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Merck Group
13.3. Viracta Therapeutics
13.4. PersonGen BioTherapeutics
13.5. Thermo Fisher Scientific
13.6. AstraZeneca
13.7. Gilead Sciences
13.8. Astex Pharmaceuticals
13.9. Immuneoncia Therapeutics
13.10. Corvus Pharmaceuticals
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us